| Literature DB >> 23162477 |
Bamidele O Adeyemo1, Marcel Simis, Debora Duarte Macea, Felipe Fregni.
Abstract
INTRODUCTION/Entities:
Keywords: motor; noninvasive brain stimulation; repetitive transcranial magnetic stimulation; stroke; transcranial direct current stimulation; transcranial magnetic stimulation
Year: 2012 PMID: 23162477 PMCID: PMC3495265 DOI: 10.3389/fpsyt.2012.00088
Source DB: PubMed Journal: Front Psychiatry ISSN: 1664-0640 Impact factor: 4.157
Baseline demographic characteristics of all selected peer-reviewed articles.
| Reference | Number of subjects | Age-mean | Age-SD | Cortical/subcortical | Hemorrhagic versus ischemic | Stroke severity (mild/mod/severe) | Females (%) | Stroke duration (months) | Oxford quality scoring system |
|---|---|---|---|---|---|---|---|---|---|
| Werhahn et al. ( | General: 20 stroke; 10 healthy | 61.5 | 13.6 | 5 Cortical; 14 subcortical (2 in pons); 1 corticosubcortical | Ischemic | Mixed based MRC (1–4) | 30% Healthy 40% | 74.40 | 1 |
| Takeuchi et al. ( | 20 | 59 | 9.6 | 20 Subcortical | Ischemic | Mixed. Based FM (25–100) | 25% | 26.95 | 2 |
| Mansur et al. ( | 10 stroke; 6 healthy | 53.3 | X | 3 Cortical and 7 subcortical | Ischemic | Mixed, hemiparesis 1 subtle/4 mild/3 moderate/1 severe/1 not specified (2 least excluded) | 70% | X | 1 |
| Khedr et al. ( | 52 | 52.85 | rTMS group: 9.5; sham group: 8.4 | Cortical 15; subcortical 26; corticosubcortical 11 | Ischemic | Moderate to severe based NIHSS | 31% | 7.20 | 0 |
| Fregni et al. ( | 6 | 53.7 | 16.60 | Cortical 1; subcortical 3; corticosubcortical 2 | NA | Mild to moderate based on MRC (3.5–4.5) | 67% | 27.10 | 1 |
| Fregni et al. ( | 15 | 57.7 | 11.27 | 2 Cortical/13 subcortical | Ischemic | Mild to moderate motor deficit | 27% | 44.05 | 2 |
| Lotze et al. ( | 7 Stroke; 7 healthy | 63.7 | 8.6 | Subcortical | Ischemic | Severely paretic or even hemiplegic at their first day after stroke, four in their left hand and three in their right hand. Almost complete recovery of motor function | 14% | 33.90 | 0 |
| Hummel and Cohen ( | 11 | 57 | 16.00 | Mostly subcortical | ischemic | Severe upper arm motor paresis (below MRC grade 2). Some of them remained unable to complete the Jebsen–Taylor Test | 55% | 41.80 | 2 |
| Richards et al. ( | 19 | 60.12 | 15.1 | Cortical, subcortical, and brain stem | Ischemic and hemorrhagic | Mixed WMTF 19.17 (SD: 18.8) | 8 | 81.60 | 3 |
| Kim et al. ( | 15 | 53.5 | 4.5 | Cortical 5 and subcortical 10 | 3 Hemorrhagic, 12 ischemic | Mild to moderate rankin (1–3) | 13% | 16.70 | 1 |
| Liepert et al. ( | 12 | 63 | 11 | Subcortical 12(2 pons) | NA | Mild based MRC (4) | 33% | 0.24 | 1 |
| Lomarev et al. ( | 7 | X | X | 2 Subcortical 5 corticosubcortical | I:6 × H:1 | Sufficient residual motor function in the paretic arm to perform pinch test dynamometry (range 25.1–31.0 lb). Patients unable to extend at the metacarpophalangeal joints at least 10–20° were also excluded from the study | 29% | X | 0 |
| Malcolm et al. ( | 19 | 67 | 6.8 | NA/NA/mixed(11 MCA; 7 lacunar; 1 unlisted); cortico + subcortical | 1 Hemorrhagic; 18 ischemic | Mixed based WMFT 15.5 ± 13.1 rTMS; 35.5 ± 33.9 sham | 42%, 8 | 45.60 | 2 |
| Hesse et al. ( | 10 | 63.3 | X | 8 Cortical; 2 subcortical | Ischemic | Severe arm paresis | 70% | X | 3 |
| Boggio et al. ( | 9 | 57.4 | 12.9 | Subcortical | NA | Mild-moderate based on MRC (3.7–4.8) | 22% | 40.90 | 1 |
| Pomeroy et al. ( | 27 | 74.8 | 12.71 | Cortical 8; subcortical 17; corticosubcortical 2 | Ischemic | Had upper limb weakness due to the stroke but able to produce at least a voluntary twitch of paretic biceps and/or triceps | 67% | 0.89 | 3 |
| Nowak et al. ( | 15 | 460,667 | 8.03 | 15 Subcortical | Ischemic | Mild based MRC (4–5) | 27% | 1.93 | 1 |
| Takeuchi et al. ( | 20 | 62.3 | 8.04 | Subcortical | Ischemic | Mixed. based FM (33–91) | 20% | 29.90 | 2 |
| Dafotakis et al. ( | 12 | 45 | 9.00 | Subcortical | Ischemic | Mild based MRC (4–5) | 33% | 1.88 | 0 |
| Mally and Dinya ( | 64 | 57.6 | 10.8 | Cortical – large hemispheric lesion | 46 Ischemic, 18 hemorrhagic | Severe | 42% | 129.60 | 0 |
| Yozbatiran et al. ( | 12 | 67 | 12.00 | Cortical 1; subcortical 11 | Ischemic, or hemorrhagic but not subarachnoid | (1) Arm motor FM score 15–55 out of 66. (2) moderate–severe arm motor deficits | 17% | 4.10 | 0 |
| Ameli et al. ( | 29 | 56 | 13.00 | Cortical 13; subcortical 16 | Ischemic | Mild-moderate | 45% | 5.50 | 0 |
| Khedr et al. ( | 36 | 57.9 | 11.00 | Cortical 19 and subcortical 17 | Ischemic | Mild to moderate | 47% | 0.57 | 1 |
| Takeuchi et al. ( | 30 | 59.3 | 12.4 | Subcortical | Ischemic | Mixed based FM | 27% | 28.80 | 2 |
| Kakuda et al. ( | 15 | 55 | 17 | Subcortical 3 (1 pons); corticosubcortical 2 | Hemorrhagic 9 × ischemic 6 | Moderate to severe based FM (17–57) | 33% | 57.00 | 0 |
| Grefkes et al. ( | 11 | 46 | 9.3 | Subcortical | Ischemic | Mild based MRC (4–5) | 18% | 1.91 | 1 |
| Khedr et al. ( | 48 | 59.52 | 13.1 | Cortical 13; Subcortical 35 | Ischemic | Mixed based NIHSS | 50% | 0.22 | 2 |
| Emara et al. ( | 60 | 53.9 | X | Cortical 22; Subcortical 38 | Ischemic | Mild to moderate hand weakness | 33% | 4.16 | 1 |
| Lindenberg et al. ( | 20 | 58.75 | 14.07/12.9 (sham) | Corticosubcortical (medial cerebral artery) | Ischemic | Severe based FM (20–56) | 20%/30% (sham) | 35.40 | 3 |
| Chang et al. ( | 28 | 56.6 | 12.2 | Cortical 11; subcortical 17 (6 pons, 2 medial medullar) | Ischemic | Mixed; mild to severe | 39%; 11 | 0.45 | 2 |
| Kim et al. ( | 18 | 57.8 | X | Cortical 5; subcortical 9; corticosubcortical 4 | Ischemic | Mixed based MRC (2–5) and FM (16–60) | 5 | 0.85 | 3 |
| Kakuda et al. ( | 5 | 66.8 | X | subcortical | 1 Hemorrhagic, 4 ischemic | Mild to moderate rankin (1–3) | 2 | 36.60 | 0 |
| Koganemaru et al. ( | 9 Stroke + 9 Healthy | 51.6 rTMS; 53.2 healthy | 11.6 rTMS; 13.8 healthy | Subcortical (1 pons) | Ischemic 7; hemorrhage 2 | Mixed based: Stroke Impairment Assessment Set (SIAS) | 55%, 5 (both) | 24.00 | 1 |
| Kakuda et al. ( | 39 | 56.5 | 16.0 | Not specified | H:23 (59); I: 16 (41) | NA (FM 36 average) | 23% | 50.30 | 0 |
| Kakuda et al. ( | 52 | 57 | 13 | Cortical and subcortical | Hemorrhagic 30 × ischemic 22 | Brunnstrom Stage 3–5 | 14 (27%) | 52.40 | 0 |
| Kakuda et al. ( | 204 | 58.5 | 13.4 | Cortical and subcortical | hemorrhagic 107 × ischemic 97 | Brunnstrom Stage 3–5 | 73 (36%) | 60.00 | 0 |
| Sasaki et al. ( | 29 | 66.96 | supratentorial subcortical | Hemorrhagic 16 × ischemic 13 | NIHSS = 6.29 | 9 (31%) | 0.56 | 1 | |
| Stagg et al. ( | 1) 13; 2) 11(Note: 7 in both; 17 total) | 64 years | Range 30–80 years | Cortical and subcortical | Hemorrhage 1; ischemic 16 | Not mentioned | 4 (23.5%) | 37.90 | 1 |
| Kakuda et al. ( | 11 | 61 | 13.7 | Subcortical | hemorrhage 7; Ischemic 4 | Brunnstrom Stage 3–5 | 5(45.4%) | 69.90 | 0 |
| Madhavan et al. ( | 9 | 65.4 | 13.2 (50–87 years) | Cortical and subcortical | Not mentioned | Lower extremity Fugl-Meyer 21–30 (maximum score 32) | 4(44.4%) | 130.80 | 0 |
| Tanaka et al. ( | 8 | 59.6 | 3.9 | Subcortical | Not mentioned | Mixed based SIAS | 4(50%) | 21.10 | 1 |
| Kakuda et al. ( | 5 | 61 | 56–66 | Subcortical | Hemorrhage 4; ischemic 1 | Brunnstrom Stage 3–5 | 2(40%) | 64.00 | 1 |
| Avenanti et al. ( | 30 | 60.9 rTMS-PT; 64.0 PT-rTMS; 64.0 sham | 8.8 rTMS-PT; 7.7 PT-rTMS; 12.1 sham | Cortical 3; corticosubcortical 1; subcortical 26 | Hemorrhage 10; ischemic 20 | Mild severity based on inclusion criteria | 47% | 31.47 | 3 |
| Bolognini et al. ( | 14 | 46.71 | 14.08 | Cortical 9; corticosubcortical 5 | Ischemic 12; hemorrhagic 2 | Moderate to severe hemiparesis, per Fugl-Meyer (Stroke duration 35.21 ± 26.45) | 64% | 35.21 | 2 |
| Conforto et al. ( | 30 | 54.8 rTMS, 56.7 sham | 11.7 rTMS, 14.8 sham | 16 Subcortical, 14 cortical | Ischemic | Mixed; mild to sever per NIHSS (range 1–11) and FM (50–123) | 40% | 0.92 | 3 |
| Hesse et al. ( | 96 | 63.9 anodal tDCS; 65.4 cathodal tDCS; 65.6 sham | 10.5 anodal tDCS; 8.6 cathodal tDCS; 65.6 sham | Mixed (cortical or corticosubcortical): 25 anodal tDCS, 24 cathodal tDCS, 26 sham tDCS. Subcortical 7 anodal tDCS, 8 cathodal tDCS, 6 sham | Ischemic | Severe per Upper extremity FM (7.8 ± 3.8 anodal tDCS, 7.9 ± 3.4 cathodal tDCS, 8.2 ± 4.4 sham; Stroke duration in weeks 3.4 ± 1.8 anodal tDCS, 3.8 ± 1.4 cathodal tDCS, 3.8 ± 1.5 sham) | 39% | 0.93 | 3 |
| Mahmoudi et al. ( | 10 | 60.8 | 14.1 | Cortical 7, subcortical 3 | Ischemic | Mild to moderate deficit (based on patients’ ability to perform all items of | |||
| Jebsen–Taylor Test (JTT) | 30% | 8.30 | 1 | ||||||
| Nair et al. ( | 14 | 55.8 | (Range 40–76) | Cortical 9, subcortical 5 | NA | Moderate to severe upper extremity impairment [per upper extremity Fugl-Meyer of 30.1 (±10.4)] | 36% | 30.50 | 2 |
| Chang et al. ( | 21 | 58.1 rTMS; sham 59.5 | 9.75 rTMS; 11.40 sham | Cortical 2, subcortical 15 | 3 Hemorrhagic, 14 ischemic | NA | 41% | 10.06 | 3 |
| Hummel et al. ( | 6 | 62.2 | 7.56 | Subcortical | Ischemic | Mild (MRC4.8 ± 0.03) | 33% | 44.30 | 1 |
The phrases ‘X’ and NA denote unavailable information.
Parameters for TDCS application parameters, placement, electrode Attributes, and employed placebo method.
| Reference | Intensity (mA) | Duration (min) | Number sections | Location anode | Location cathode | Electrode (info and size) | Type of placebo | Concomitant therapy or motor tasks |
|---|---|---|---|---|---|---|---|---|
| Hummel and Cohen ( | 1 | 20 | 1 | Motor ipsilesional side | Contralateral Supraorbital | 25 cm2 | 30 s | N/A |
| Hesse et al. ( | 1.5 | 7 | 30 | Motor ipsilesional side | Contralateral Supraorbital | 35 cm2 | No sham | Robot-assisted arm training |
| Fregni et al. ( | 1 | 20 | 1 | Ipsilesional side Or Supraorbital | Contralesional or supraorbital | 35 cm2 | 30 s | N/A |
| Boggio et al. ( | 1 | 20 | (1) 1 and (2) 5 | (1) Ipsilesional side or supraorbital; (2) Supraorbital | (1) Contralesional side or supraorbital (2) contralesional side | 35 cm2 | 30 s | N/A |
| Lindenberg et al. ( | 1.5 | 30 | 5 | Motor ipsilesional side | Motor contralesional side | 16.3 cm2 | 30 s | Physical and occupational therapy |
| Kim et al. ( | 2 | 20 | 10 | Ipsilesional side Or Supraorbital | Contralesional or Supraorbital | 25 cm2 | 60 s | Conventional, physical, and occupational therapy |
| Stagg et al. ( | 1 | (1) 20 (2) 10 | 1 session (3 total crossover) | Motor ipsilesional side or supraorbital | Motor contralesional side or supraorbital | 35 cm2 | 10 s (vertex) | N/A |
| Madhavan et al. ( | 0.5 | 15 | 1 session (3 total crossover) | Motor ipsilesional side or contralesional (Leg) | Contralateral Supraorbital | 8 cm2 (anode) 48 cm2 (cathode) | 10 s | N/A |
| Tanaka et al. ( | 2 | 10 | 1 session (2 total crossover) | Motor ipsilesional side (Leg) | Contralateral Supraorbital | 35 cm2 (anode) 50 cm2 (cathode) | 15 s | N/A |
| Bolognini et al. ( | 2 | 40 | 10 | Ipsilesional side | Contralesional side | 35 cm2 | 30 s | Constraint-induced movement therapy |
| Hesse et al. ( | 2 | 20 | 30 | Group A: ipsilesional side; Group B: contralesional side; sham: A or B set-up changing consecutively | Group A: contralateral orbit; Group B: contralateral supraorbit area; Sham: A or B set-up changing consecutively | 35 cm2 | 0 mA | Robot-assisted arm training |
| Mahmoudi et al. ( | 1 | 20 | 1 session (5 total crossover) | Bilateral tDCS group: ipsilesional side; Anodal tDCS group: ipsilesional side; Cathodal tDCS group: contralateral supraorbital area; Extra-cephalic tDCS group: ipsilesional side; Sham tDCS group | Bilateral tDCS group: contralesional side; Anodal tDCS group: Contralateral supraorbital; Cathodal tDCS group: contralesional side; Extra-cephalic tDCS group: contralateral deltoid muscle; Sham tDCS group: Not listed | 35 cm2 | 30 s | N/A |
| Nair et al. ( | 1 | 30 | 5 | Contralateral supraorbital area | Contralesional | NA | Stimulation intensity turned off at unspecified interval | Occupational therapy |
| Hummel et al. ( | 1 | 20 | 2 | Ipsilesional | Contralateral supraorbital | 25 cm2 | 30 s | N/A |
rTMS parameters, application location, duration of treatment, and placebo implementation.
| Reference | TMS type | Frequency | Intensity % motor threshold | Number of stimuli per train | Type of placebo or active control | Concomitant Therapy or motor tasks |
|---|---|---|---|---|---|---|
| Fregni et al. ( | Contralesional | 1 Hz | 100% | 1200 | Sham coil | N/A |
| Takeuchi et al. ( | Contralesional | 1 Hz | 90& | 1500 | 90° | N/A |
| Mansur et al. ( | Contralesional | 1 Hz | 100% | 600 | Sham coil | N/A |
| Werhahn et al. ( | (1, 2, and 4) Contralesional and Ipsilesional (3) Ipsilesional | (1) Single (2) 1 Hz; (3) 1 Hz; (4) single | (1) 130%; (2) 150%; (3) 150%; (4) 130% | (1) | Vertex (control stimulation) | N/A |
| Nowak et al. ( | Contralesional | 1 Hz | 100% | 10 | Vertex (control stimulation) | N/A |
| Takeuchi et al. ( | Contralesional | 1 Hz | 90% | 1500 | 90° | N/A |
| Dafotakis et al. ( | Contralesional | 1 Hz | 100% | 600 | Vertex (control stimulation) | N/A |
| Kakuda et al. ( | Contralesional | 1 Hz | 90% | 1200 | No sham | Intensive occupational therapy (OT) |
| Liepert et al. ( | Contralesional | 1 Hz | 90% | 1200 | Sham coil | N/A |
| Grefkes et al. ( | Contralesional | 1 Hz | 100% | 600 | Vertex (control stimulation) | N/A |
| Lotze et al. ( | Contralesional | 20 Hz | 120% | 3 | 90° | N/A |
| Lomarev et al. ( | Ipsilesional | 20 and 25 Hz | 110, 120, and 130% | 10 and 20 | 90° | N/A |
| Malcolm et al. ( | Ipsilesional | 20 Hz | 90% | 40 | Attaching surface electrodes underneath the magnetic coils and in contact with the scalp connected to the electromyography | Constraint-induced therapy |
| Khedr et al. ( | Ipsilesional | 3 Hz | 120% | 30 | Coil angled away from the head | Continued to receive their normal therapy |
| Khedr et al. ( | Ipsilesional | 3 and 10 Hz | (1) 130%; (2) 100% | Group (1) 14, Group (2) 20 | Coil angled away from the head | combination with conventional therapy |
| Yozbatiran et al. ( | Ipsilesional | 20 Hz | 90%; and 7 patients 60% device output | 40 | No sham | N/A |
| Ameli et al. ( | Ipsilesional | 10 Hz | 80% | 50 | Vertex (control stimulation) | N/A |
| Emara et al. ( | Contralesional and ipsilesional side | 1 and 5 Hz | 80–90% ipsilesional 110–120% contralesional | (1) 750 pulses; (2) 150 pulses | 90° | received standard physical therapy |
| Pomeroy et al. ( | Ipsilesional | 1 Hz | 120% MT | 40 | Sham coil | Voluntary muscle contraction (real and placebo) They were asked to flex and extend the paretic elbow and to continue to repeat or to attempt this for 5 min |
| Chang et al. ( | Ipsilesional | 10 Hz | 90% | 1000 | 90° | Motor practice consisted of 50 s of reaching and grasping exercises, which were conducted after each rTMS. Plus conventional, physical, and occupational therapy |
| Kakuda et al. ( | Contralesional | 1 Hz | 90% | 1200 | 90° | Occupational therapy |
| Kakuda et al. ( | Contralesional | 1 Hz | 90% | 1200 | No sham | Occupational therapy |
| Koganemaru et al. ( | Ipsilesional | 5 Hz; | 100% of the active motor threshold | (1) 600; (3) 7200 | (1) Sham coil; (3) no sham | Exercises for the extensors of the wrist and fingers |
| Richards et al. ( | Ipsilesional | 20 Hz | 90% | 2000 | Surface electrodes under the magnet sham rTMS | Constraint-induced movement therapy |
| Kim et al. ( | Ipsilesional | 10 Hz | 80% | 20 | 90° | N/A |
| Khedr et al. ( | Contralesional and ipsilesional side | (1) 1 Hz; (2) 3 Hz | (1) 100%; (2) 130% | 900 pulses | Coil angled away from the head | conventional therapy |
| Takeuchi et al. ( | (1) Contralesional; (2) ipsilesional; (3) bilateral | (1) 1 Hz; (2) 10 Hz; (3) 1 and 10 Hz | 90% | (F1) 1000; (F2) 1000; (F3) 2000 | 90° | N/A |
| Mally and Dinya ( | Contralesional and ipsilesional side | 1 Hz | (30% of 2.3 T) | 100 | No sham | N/A |
| Kakuda et al. ( | Contralesional | 1 Hz | 90% | 1200 | No sham | Intensive occupational therapy (OT) |
| Kakuda et al. ( | Contralesional | 1 Hz | 90% | 1200 | No sham | Intensive occupational therapy (OT) |
| Sasaki et al. ( | Contralesional or ipsilesional side | (1) 1 Hz or (2) 10 Hz | 90% | 1800 or 1000 | 90° | N/A |
| Kakuda et al. ( | Contralesional | 6 Hz (priming per 10 min) + 1 Hz per 20 min | 90% | 600 + 1200 = 1800 | No sham | Intensive occupational therapy (OT) |
| Kakuda et al. ( | Contralesional | 1 Hz | 90% | 1200 | No sham | Intensive occupational therapy (OT) + Levodopa |
| Avenanti et al. ( | Contralesional | 1 Hz | 90% | 1500 pulses (1 train) | 90° | physical therapy |
| Conforto et al. ( | Contralesional | 1 Hz | 90% | 1500 pulses (1 train) | 90° | Therapies to outpatient customary rehabilitation, |
| Chang et al. ( | Ipsilesional | 10 Hz | 80% | 50 pulses × 20 trains × 10 daily sessions = 10,000 total | 90° | N/A |
*Values for each experiment group are separated by bracketed numbers. For example, if an experiment has three groups, the information per group is listed as (1), (2), and (3), respectively.
Inventory of motor assessment tools and reported outcome in selected transcranial Stimulation articles.
| Reference | MRC | JTHF | HG | PF | PA | FM | PTT | sRT | cRT | MRs | NIHSS | FT | RGM | ASS | WMFT | ARAT | MA.Log | BBT | BIS | ASMI | LSMI | FAC | B | Others |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fregni et al. ( | B | # + | N | N | N | N | # + | # + | # + | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N |
| Takeuchi et al. ( | N | N | N | Φ | + | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N |
| Mansur et al. ( | N | N | N | N | N | N | + | + | + | N | N | Φ | N | N | N | N | N | N | N | N | N | N | N | N |
| Werhahn et al. ( | B | N | N | N | N | B | N | Δ | N | N | N | ♦ | N | N | N | N | N | N | N | N | N | N | N | N |
| Nowak et al. ( | B | N | N | N | N | N | N | N | N | B | B | + | + | N | B | N | N | N | N | N | N | N | N | N |
| Takeuchi et al. ( | N | N | N | # + | # + | B | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N |
| Dafotakis et al. ( | B | N | N | + | + | N | N | N | N | B | B | N | N | N | N | B | N | N | N | N | N | N | N | N |
| Kakuda et al. ( | N | N | N | N | N | N | N | N | N | N | N | N | * | * | N | N | N | N | N | N | N | B | N | |
| Liepert et al. ( | B | N | Φ | N | N | N | Φ | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N |
| Grefkes et al. ( | B | N | N | N | N | N | N | N | N | B | B | N | N | N | N | B | N | N | N | N | N | N | N | Written instructions on a monitor visible through a mirror whether to move the left, right, or both hands in the upcoming task-block (+) |
| Lotze et al. ( | B | N | N | N | N | N | N | N | N | N | N | Δ | N | N | N | N | N | N | N | N | N | N | N | N |
| Lomarev et al. ( | N | N | N | Φ | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N |
| Malcolm et al. ( | N | N | N | N | N | N | N | N | N | N | N | N | N | N | Φ | N | Φ | Φ | N | N | N | N | N | N |
| Khedr et al. ( | N | N | N | N | N | N | N | N | N | N | # + | N | N | N | N | N | N | N | # + | N | N | N | N | SSS# + |
| Khedr et al. ( | N | N | *# | N | N | N | N | N | N | # | + | N | N | N | N | N | N | N | N | N | N | N | N | Shoulder abduction #; Dorsiflexion of toes Hip flexion#; Toe dorsiflexion# (only after 1 year fir 10 Hz) |
| Yozbatiran et al. ( | N | N | * | N | N | Ξ | * | N | N | N | N | N | N | N | N | Φ | N | N | Φ | N | N | N | N | Active ranges of motion at the affected side wrist and index finger metacarpophalangeal joint. |
| Ameli et al. ( | B | N | N | N | N | N | N | N | N | B | B | (+) And hand tapping + | N | N | N | B | N | N | N | N | N | N | N | N |
| Hummel and Cohen ( | B | N | N | + | N | B | N | + | N | N | N | N | N | B | N | N | N | N | N | N | N | N | N | N |
| Hesse et al. ( | * | N | N | N | N | * | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N |
| Fregni et al. ( | B | + | N | N | N | N | N | N | N | N | N | N | N | B | N | N | N | N | N | N | N | N | N | N |
| Emara et al. ( | N | N | N | N | N | N | N | N | N | # + | N | + | N | N | N | N | N | N | N | N | N | N | N | Activity Index (AI) scale# + |
| Boggio et al. ( | B | # + | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | |
| Pomeroy et al. ( | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | Φ | N | N | N | N | N | N | N | Peak torque about the elbow during isotonic concentric flexion/extension. |
| Lindenberg et al. ( | B | N | N | N | N | # + UE | N | N | N | N | N | N | N | N | # + | N | N | N | N | N | N | N | N | For fMRI, performing repetitive elbow and wrist extension/flexion movements |
| Chang et al. ( | N | N | # + | N | N | (1) UE + (2) LL | N | N | N | N | N | N | N | N | N | N | N | Φ | Φ | # + | Φ | Φ | Φ | N |
| Kim et al. ( | B | N | N | N | N | # | N | N | N | B | B | N | N | N | N | N | N | N | Φ | N | N | N | B | N |
| Kakuda et al. ( | N | N | N | N | N | Ξ * | N | N | N | N | N | N | N | Ξ* | * | N | N | N | N | N | N | N | N | N |
| Kakuda et al. ( | N | N | N | N | N | Ξ * | N | N | N | N | N | N | N | N | Ξ * | N | N | N | N | N | N | N | B | Ten seconds test X * |
| Koganemaru et al. ( | N | N | (A) + (after 30 min); (B) Ξ * | (B) Ξ * | N | N | N | N | N | N | N | N | N | (A) +; (B) Ξ * | N | N | N | N | N | N | N | N | N | (A) Active range of movement +(B) active range of movement X *; passive range of movement X * |
| Richards et al. ( | N | N | N | N | N | N | N | N | N | N | N | N | N | N | Φ | N | N | N | N | N | N | N | N | Motor Activity Log.3 |
| Kim et al. ( | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | Finger motor task. (1) Movement accuracy (MA) + (2) movement time (MT) + |
| Khedr et al. ( | N | N | Φ | N | N | N | # + | N | N | N | # + | # + | N | N | N | N | N | N | # + | N | N | N | N | Keyboard tapping#* |
| Takeuchi et al. ( | N | N | N | # + | # + | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N |
| Mally and Dinya ( | N | N | N | N | N | Ξ * | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | Score of spasticity at rest X * |
| Kakuda et al. ( | N | N | N | N | N | * | N | N | N | N | N | N | N | N | * | N | N | N | N | N | N | N | B | N |
| Kakuda et al. ( | N | N | N | N | N | Ξ * | N | N | N | N | N | N | N | N | Ξ * | N | N | N | N | N | N | N | B | N |
| Sasaki et al. ( | N | N | + | N | N | N | N | N | N | N | B | + | N | N | N | N | N | N | N | N | N | N | B | N |
| Stagg et al. ( | N | N | (1) Φ | N | N | N | N | (2) (+) | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | (1) Response times (+); (2) choice response time condition (Φ). |
| Kakuda et al. ( | N | N | N | N | N | * | N | N | N | N | N | N | N | N | * | N | N | N | N | N | N | N | B | N |
| Madhavan et al. ( | N | N | N | N | N | B | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | Tracking a sinusoidal waveform (+) |
| Tanaka et al. ( | N | N | Φ | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | SIAS (B); MFKE(+) |
| Kakuda et al. ( | N | N | N | N | N | * Ξ | N | N | N | N | N | N | N | * | * Ξ | N | N | N | N | N | N | N | N | N |
| Avenanti et al. ( | N | +# | =# | PG# +; force + | N | N | N | N | N | N | N | N | N | N | N | N | N | +# | N | N | N | N | N | NHPT +# |
| Bolognini et al. ( | N | +# | + | N | N | + | N | N | N | N | N | N | N | N | N | N | +# | N | N | N | N | N | N | N |
| Conforto et al. ( | N | +# | N | + | N | + | N | N | N | + | B | N | N | Φ | N | N | N | N | N | N | N | N | N | N |
| Hesse et al. ( | +# | N | N | N | N | +# | N | N | N | N | N | N | N | +# | N | N | N | +# | +# | N | N | N | N | N |
| Mahmoudi et al. ( | N | + | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | B | |
| Nair et al. ( | N | N | N | N | N | + | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | Mean ROM shoulder abduction, elbow extension and wrist extension + |
| Chang et al. ( | N | + | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | Sequential motor task – accuracy (MA) + |
| Hummel et al. ( | B | + | N | N | N | B | N | N | N | N | N | N | N | B | N | N | N | N | N | N | N | N | N | Hand ability B |
JTHF, Jebsen–Taylor hand function test; MRC, Medical Research Council scale; HG, hand grip; PF, pinch force; PA, pinch acceleration; FM, Fugl-Meyer assessment, PTT, Purdue Pegboard test; sRT, simple reaction time test, cRT, choice reaction test; MRs, modified rankin score; NIHSS, National Institutes of Health Stroke Scale; FT, finger tapping (with different tasks); RGM, reach to grasp movement, ASS, Ashworth spasticity scale; WMFT, wolf motor function test; ARAT, action research arm test; MA.Log, motor activity log; BBT, box and block test; BIS, Barthel index scale; ASMI, arm score of motricity index; LSMI, leg score of motricity index; FAC, functional ambulatory category; B, Brunnstrom; SSS, Scandinavian stroke scale; UE, upper extremity; LL, lower limb; SIAS, stroke impairment assessment set; MFKE, maximal force of knee extension. (B) = apply in baseline only; (Δ) = negative; (Φ) = no significant change; (*) = positive, but no placebo control; (+) = positive; (#) = long-term positive; (Ξ) = long-term positive, but placebo control; (♦) = affect.
Figure 1Forest plot of the subset of studies with amenable and data-available for systematized comparison, with the pooled effect size for studies of transcranial stimulation on motor.
Figure 2Assessment of the fixed effects size estimates in linear form with effect size as Cohen’s .
Figure 3Funnel plot representing publication bias assessment of the effect sizes (Cohen’s . The pooled effect size is represented by the horizontal solid line. The 94% confidence interval expected for each is represented by the diagonal lines. (Of note, this graph assumes no heterogeneity between studies.)